Lucchetta Rosa Camila, Riveros Bruno Salgado, Pontarolo Roberto, Radominski Rosana Bento, Otuki Michel Fleith, Fernandez-Llimos Fernando, Correr Cassyano Januário
Laboratory of Clinical Services and Evidence in Health, Pharmacy Department, Universidade Federal do Paraná (UFPR), Curitiba, PR, Brazil.
Service of Endocrinology and Metabolism, Hospital de Clínicas, UFPR, Curitiba, PR, Brazil.
Rev Assoc Med Bras (1992). 2017 Mar;63(3):203-206. doi: 10.1590/1806-9282.63.03.203.
Antiobesity pharmacotherapy remains the main point of disagreement among both scientists and regulators. This is probably due to small sample sizes, high levels of heterogeneity, and low methodological quality. For many years, Brazil was one of the largest consumers of appetite suppressants worldwide, with evidence of irrational use of this drug class. Therefore, the country was the scene of a debate that divided the Brazilian Health Surveillance Agency (Anvisa - Agência Nacional de Vigilância Sanitária) and medical societies over the maintenance record of diethylpropion, mazindol and fenproporex. In this context, this commentary presents new arguments to contribute to the discussion, as well as recommendations for future studies.
抗肥胖药物治疗仍然是科学家和监管机构之间存在分歧的主要焦点。这可能是由于样本量小、异质性高以及方法学质量低所致。多年来，巴西是全球食欲抑制剂最大的消费国之一，有证据表明这类药物存在不合理使用的情况。因此，该国成为了一场辩论的舞台，这场辩论使巴西卫生监督局（Anvisa - 国家卫生监督局）和医学协会在二乙丙醇胺、马吲哚和苯丙醇胺的保留记录问题上产生了分歧。在此背景下，本评论提出了有助于讨论的新论据以及对未来研究的建议。
